First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
BeOne terminates a MUC1-targeting project.
A binary Xpovio catalyst is set for March.
Welireg, Padcev, and a surprise fillip for Flare.
Two new pivotal Chinese first-line trials have started in lung cancer.
AZD0120’s first pivotal trial will test settings as early as the second line.
